Replay earlier webinars
Our previous webinars are free to access. Replay them at your convenience to gain more flexibility, deepen your understanding, and foster professional development.
2024
Symposium : 7th June 2024
MAFLD in Focus : Unveiling Insights from China's RELIEF Study - Insights from APASL 2024
Metabolic and Toxic Liver Damage in focus – MANPOWER’s Latest Breakthroughs Revealede
Shedding Light on Genomic, Metabolic, and Phenotypic Effects of Essential Phospholipids on HepaRG
Metabolic Comorbidities Unmasked - Redefining MASLD/MASH Impact
Opella exhibition space: 7th June 2024
Effectiveness of Polyene phosphatidylcholine in metabolic-associated fatty liver disease treatment: A real-world study in China
Screening and alleviation of burden of MASLD/MAFLD - importance of metabolic and cardiovascular risk
Early risk identification of liver disease and MASLD and Place of hepatoprotective adjunctive treatment options
EASL Studio Roundtable : 7th June 2024
MASLD anno 2024: A rapidly changing landscape
2023
Webinar 1: 21st June 2023 – Symposium
To what extent can HRQoL impact clinical outcomes in MAFLD?
Metabolic and Toxic Liver Damage in focus – MANPOWER’s Latest Breakthroughs Revealede
MAFLD – the importance of early identification and intervention
MAFLD-associated metabolic risks in obesity and diabetes – insights from clinical practice
Webinar 2: 21st June 2023 – Expert Meeting
Insights from the SIRIUS project – a population-wide liver disease screening program in Slovakia
Tools for early detection of metabolic risk in MAFLD
Early screening of metabolic risk – the pharmacists’ perspective
2022
Webinar 1: friday, 13th may 2022
Essential Phospholipids
Membrane protection against NAFLD & NASH
MAFLD & Covid-19
Overview the progress of NASH treatment
Webinar 2: friday, 7th oct. 2022
Cardiovascular and metabolic risks of MAFLD - implications for clinical practice
Potential molecular mechanisms of EPL - insights from EASL 2022
Drug-induced liver injury (DILI) - the importance of early detection
Global Liver Institute’s Annual Report
2021
Webinar 1: friday, 4th june 2021
From NAFLD to MAFLD - the importance of steatosis in the paradigm shift
Detecting steatosis in clinical practice - insights from the EPOCH
Essential phospholipids - latest evidence reviewed
Digital trends in healthcare - the potential impact on NALFD
Webinar 2: friday, 8th oct. 2021
Early diagnostics of NAFLD – spotting warning signs to prevent progression
Healthcare practitioners’ diagnostic and treatment practice patterns of non-alcoholic fatty liver disease in Poland – a real-world evidence study
The importance of fast identification and understanding disease progression – key notes for NAFLD management
Essential phospholipids – efficacy across the spectrum of NAFLD origins
Webinar 3: friday, 22nd oct. 2021
Putting MAFLD into perspective – liver-directed hepatoprotective treatment options
Hepatic steatosis in MAFLD – importance of early intervention
Essential phospholipids – new perspectives on the MoA
REPAIR study insights – essential phospholipids across the liver health continuum
Efforts for early detection and screening of NAFLD, and global burden of NAFLD
2020
Webinar 1: friday, 23rd oct. 2020
Insights into NAFLD burden and epidemiology. What does the data tell us? Global insights
NAFLD and metabolic comorbidities. Current understanding and perspectives
Therapeutic approaches for NAFLD
Importance of RWE in understanding the current disease landscape: MANPOWER results put into perspective
Webinar 2: saturday, 24th oct. 2020
What does a NAFLD patient journey look like? Importance of HR-QoL
Emerging role of hepatoprotective treatment options
Essential phospholipids. Mechanism of action in liver disease explained
The role of the essential phospholipids in NAFLD continuum
.2023-01-30-10-21-42.2023-01-30-10-21-42.png)